Complex pharmacies are on May 22 to stop Semagluide sales
On May 22, complex pharmacies should stop the Semaglutide injection, which is used as a cheaper general alternative to Ozempic and Wegovy. This decision is based on a judge’s rejection of the official request for official sales.
Fox -10 Phoenix
Novo Nordisk, a pharmaceutical company in Denmark, announced that it has temporarily reduced the price of weight loss drugs for new customers, attempting to restrict the sale of a compound version of the drug version.
NOVO NORDISK will sell one supply of WEGOVY from $ 199 to June 30 for one month for patients who have previously taken combined versions of drugs. This announcement matches the federal deadline on May 22, and manufacturers can stop the cheap composite version of drugs.
Novo Nor Disc officials said that one -time discounted prices are for those who have to pay drug costs because they are not insured or health insurance does not deal with it. The price will be returned to $ 499 after June 30.
“We want to meet patients when we are there when we are there and when we switch from composite (version) to actual Wegovy,” said Dave Moore, vice president of NOVO NORDISK.
Novo Nordisk and ELI Lilly have been closely investigated on the price of popular diabetes and obesity drugs known as GLP -1 or glucagon -like peptide -1 (or glucagon -like peptide -1).
Insurance companies often deal with GLP-1 drugs when prescribing diabetes or heart condition, but many insurers are reluctant to cover obese drugs. Some Blue Cross Blue Shield plan It will not cover the drug for weight loss at all.
In April, the Trump administration rejected the BIDEN proposal to expand the Medicare report on weight loss drugs.
Consumers who welfare for pharmacies to buy cheap drugs no longer have that option.
The federal government has allowed pharmacies to sell pharmacy pharmacies so that pharmacies can sell GLP-1 drugs. But the Food and Drug Administration said that the lack of Zepbound in Wegovy and ELI Lilly was over.
As of May 22, the manufacturer can no longer distribute a composite version of Semaglutide, and Novo Nordisk cannot distribute a composite version of Semaglutide, which is sold by WEGOVY brand and diabetes Ozemic for weight loss.
The Industrial Trade Group Outsourcing Facility Association has submitted the Texas US District Court to sue and delay the execution. But the federal judge rejected the group’s consent.
LEE ROSBUSH, chairman of the industry group, said that the patient’s approach to the drug went back to a tremendous step.
He said that the FDA depended on the data supplied by the pharmaceutical company and declared that the GLP-1 drug was no longer lacking, and ended the legal road for selling cheap copies.
Rosebush said, “The FDA registration outsourcing facility will no longer create a combination of GLP-1 drugs, and especially as major insurers refuse to cover GLP-1, Rosebush said,” Rosebush said. “We urge patients to be affected by the FDA’s behavior to contact the parliament and the FDA directly to share the lack of deficiency removal to health and welfare.”
Novo Nordisk announced in April that it will partner with TeleHealth company HIMS & HERS, LIFEMD and RO.
Telehealth Company RO said it will reduce the first month of the membership fee to $ 45. The fee includes a licensed prescriber, custom coaching, side effect monitoring and other services, the company said.
Novo Nordisk said that new customers can get a one -off $ 199 price through the company’s Novocare Pharmacy. Customers who have been prescribed by a doctor can visit Wegovy.com to print or send them by cell phone. One -time $ 199 is provided through a remote healthy company, which may be charged with its own conditions and charges.
February, Eli Lily Lower the monthly price In the case of low -dose vials of obesity drugs, a $ 50 plunder for consumers paying cash through drugmaker. Lily Director Website. Lily’s price depends on the dose. Customers who buy a monthly supply of 2.5 mg vials pay $ 349 and 5 mg of vials are $ 499.
